Isarna Therapeutics
Develop selective TGF-β inhibitors to effectively treat ophthalmic diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
$7.6m | Early VC | ||
| Total Funding | 000k | ||
| EUR | 2020 | 2021 |
|---|---|---|
| Revenues | 0000 | 0000 |
| EBITDA | 0000 | 0000 |
| Profit | 0000 | 0000 |
| EV | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 |
Source: Company filings or news article
Related Content
Isarna Therapeutics is a biotechnology company specializing in the development of antisense therapies aimed at blocking the production of TGF Beta, a key mediator of fibrosis in the eye and other organs such as the liver and lung. The company operates in the biopharmaceutical market, focusing on innovative treatments for conditions like neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Isarna's business model revolves around advancing its pipeline of antisense molecules through clinical trials, with the goal of bringing these therapies to market. Revenue is generated through partnerships, licensing agreements, and potential future sales of approved therapies. The company serves patients suffering from fibrotic diseases and eye conditions, as well as the broader medical community engaged in treating these ailments.
Keywords: antisense therapies, TGF Beta, fibrosis, eye diseases, nAMD, DME, biotechnology, clinical trials, biopharmaceutical, innovative treatments.